Arcus Biosciences: Casdatifan Takes Center Stage After STAR-221 [Seeking Alpha]
Arcus Biosciences, Inc. (RCUS)
Last arcus biosciences, inc. earnings: 3/5 04:10 pm
Check Earnings Report
Company Research
Source: Seeking Alpha
Instead, they'll focus now on Casdatifan (AB521), which is a wholly owned oral HIF-2a inhibitor. In my view, this makes Casdatifan the core bull thesis, especially with the Phase 3 PEAK-1 results going forward. Yet there are also other interesting catalysts for 2026. RCUS has pipeline optionality with quemliclustat, for example. I feel RCUS's valuation has some premium embedded at these levels. But, long-term investors should profit nicely if RCUS ultimately succeeds with Casdatifan. Solskin/DigitalVision via Getty Images Arcus Biosciences, Inc. ( RCUS ) is a biopharmaceutical company that develops drugs designed to be used in combination with other agents, rather than as standalone treatments. RCUS is undergoing a strategic reset after the discontinuation of its This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hour
Show less
Read more
Impact Snapshot
Event Time:
RCUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCUS alerts
High impacting Arcus Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
RCUS
News
- This Growth Stock With 137% Upside Faces New Challenge: Buy, Hold or Sell? [Yahoo! Finance]Yahoo! Finance
- Arcus Biosciences (NYSE:RCUS) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- Why Arcus Biosciences (RCUS) Is Down 15.4% After Halting Key Domvanalimab Cancer Trials And What's Next [Yahoo! Finance]Yahoo! Finance
- Arcus Biosciences (NYSE:RCUS) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=RCUS&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street ZeMarketBeat
- Arcus Biosciences (NYSE:RCUS) had its "buy" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
RCUS
Earnings
- 8/6/25 - Beat
RCUS
Sec Filings
- 12/15/25 - Form 144
- 12/15/25 - Form 144
- 12/15/25 - Form 144
- RCUS's page on the SEC website